<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04735042</url>
  </required_header>
  <id_info>
    <org_study_id>AS0005</org_study_id>
    <nct_id>NCT04735042</nct_id>
  </id_info>
  <brief_title>SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.</brief_title>
  <acronym>UTI-flog</acronym>
  <official_title>Use of Combination Empagliflozin/Linagliptin or Dapagliflozin/Saxagliptin vs Empagliflozin or Dapagliflozin Alone, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pisa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pisa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this observational study, 60 subjects with type 2 diabetes (T2D) and eligible, as per good&#xD;
      clinical practice, for therapy with SGLT-2 inhibitor, will be randomized to receive a SGLT-2&#xD;
      inhibitor or a fixed dose combination of SGLT-2 inhibitor with a DPP4-inihibitor for 12&#xD;
      weeks. Measures will be performed at baseline and after 12 weeks of treatment, as per good&#xD;
      clinical practice.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The day of the study patients undergo a routine clinical evaluation. Whole blood samples will&#xD;
      be collected from an antecubital vein to assess serum/plasma aliquots of 200 μl each (frozen&#xD;
      at -80°C until required for quantitation) for evaluation of biochemical parameters (fasting&#xD;
      glucose, HbA1c, lipid profile, serum creatinine, uric acid, electrolytes, liver function&#xD;
      enzymes, albumin).&#xD;
&#xD;
      A mid-stream first urine in the morning sample will be collected into a sterile container. 50&#xD;
      ml of urine will be immediately transferred into a sterile falcon and centrifugated at 4500&#xD;
      rpm for 10 min. After removal of the supernatant and addition of 10 ml of PBS or sterile&#xD;
      physiological solution, the sample will be further centrifugated at 4500 rpm for 10 min. The&#xD;
      supernatant will be removed and the pellet stored in a falcon at -80°C.&#xD;
&#xD;
      Genomic DNA will be extracted throw Qiamp DNA mini kit (QIAGEN) and quantified using&#xD;
      spectrophotometric assay.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 7, 2020</start_date>
  <completion_date type="Anticipated">April 7, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 7, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in metagenomic analysis based on rRNA 16S gene</measure>
    <time_frame>Each patients will be analyzed at baseline and after 12 weeks</time_frame>
    <description>Metagenomic analysis based on rRNA 16S gene will be performed by Novogene on Illumina platform (Hong Kong, China)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline of total bacterial load</measure>
    <time_frame>Each patients will be analyzed at baseline and after 12 weeks</time_frame>
    <description>Absolute quantification of total bacterial load in the original sample using real-Time quantitative PCR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting glucose</measure>
    <time_frame>baseline and 12 week</time_frame>
    <description>Fasting glucose measured in a fasting morning blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycated Haemoglobin</measure>
    <time_frame>baseline and 12 week</time_frame>
    <description>HbA1c in a fasting measured in a morning blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>baseline and 12 week</time_frame>
    <description>Using creatinine measured in a fasting morning blood sample and estimated by eGFR (calculated with the CDK-EPI formula)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin excretion</measure>
    <time_frame>baseline and 12 week</time_frame>
    <description>Measured by urinary albumin/creatinine ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>baseline and 12 week</time_frame>
    <description>Total cholesterol measured in a fasting morning blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL cholesterol</measure>
    <time_frame>baseline and 12 week</time_frame>
    <description>HDL cholesterol measured in a fasting morning blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>baseline and 12 week</time_frame>
    <description>Triglycerides measured in a fasting morning blood sample</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>SGLT2 and DPP-4 inhibitors</arm_group_label>
    <description>Patients undergoing SGLT2i and DPP4i.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SGLT2 inhibitors only</arm_group_label>
    <description>Patients undergoing SGLT2i alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin / Linagliptin or Dapagliflozin/Saxagliptin Pill</intervention_name>
    <description>association between SGLT2-inhibitor and DPP4-inhibitor</description>
    <arm_group_label>SGLT2 and DPP-4 inhibitors</arm_group_label>
    <other_name>Glyxambi or Qtern</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin or Dapagliflozin Pill</intervention_name>
    <description>SGLT2-inhibitor: diabetic oral drug with diuretic properties.</description>
    <arm_group_label>SGLT2 inhibitors only</arm_group_label>
    <other_name>Jardiance or Forxiga</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum Urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study will consecutively enrolled 60 patients among those referring to the Departiment&#xD;
        of Diabetes and Metabolic disease, Santa Chiara Hospital, Pisa.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes diagnosis&#xD;
&#xD;
          -  Hb1Ac ≥ 7% and ≤ 9%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hb1Ac &gt; 9%&#xD;
&#xD;
          -  current treatment with an SGLT2i or a DPP4i drugs, or in the prior 4 week&#xD;
&#xD;
          -  irritating and/or obstructive urinary or genital symptoms&#xD;
&#xD;
          -  menstrual cycle for women&#xD;
&#xD;
          -  current antibiotic treatment or in the prior 4 weeks&#xD;
&#xD;
          -  anatomical or functional abnormalities of the urinary tract (e.g. incontinence,&#xD;
             neurological bladder, bladder prolapse).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Solini, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pisa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Solini, MD, PhD</last_name>
    <phone>050993482</phone>
    <phone_ext>+39</phone_ext>
    <email>anna.solini@med.unipi.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Pisa</name>
      <address>
        <city>Pisa</city>
        <zip>56125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Solini, MD, PhD</last_name>
      <phone>+39050993482</phone>
      <email>anna.solini@med.unipi.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Nitzan O, Elias M, Chazan B, Saliba W. Urinary tract infections in patients with type 2 diabetes mellitus: review of prevalence, diagnosis, and management. Diabetes Metab Syndr Obes. 2015 Feb 26;8:129-36. doi: 10.2147/DMSO.S51792. eCollection 2015. Review.</citation>
    <PMID>25759592</PMID>
  </reference>
  <reference>
    <citation>Renko M, Tapanainen P, Tossavainen P, Pokka T, Uhari M. Meta-analysis of the significance of asymptomatic bacteriuria in diabetes. Diabetes Care. 2011 Jan;34(1):230-5. doi: 10.2337/dc10-0421. Epub 2010 Oct 11. Review.</citation>
    <PMID>20937688</PMID>
  </reference>
  <reference>
    <citation>Schmiemann G, Kniehl E, Gebhardt K, Matejczyk MM, Hummers-Pradier E. The diagnosis of urinary tract infection: a systematic review. Dtsch Arztebl Int. 2010 May;107(21):361-7. doi: 10.3238/arztebl.2010.0361. Epub 2010 May 28. Review.</citation>
    <PMID>20539810</PMID>
  </reference>
  <reference>
    <citation>He K, Hu Y, Shi JC, Zhu YQ, Mao XM. Prevalence, risk factors and microorganisms of urinary tract infections in patients with type 2 diabetes mellitus: a retrospective study in China. Ther Clin Risk Manag. 2018 Feb 26;14:403-408. doi: 10.2147/TCRM.S147078. eCollection 2018.</citation>
    <PMID>29520146</PMID>
  </reference>
  <reference>
    <citation>Aswani SM, Chandrashekar U, Shivashankara K, Pruthvi B. Clinical profile of urinary tract infections in diabetics and non-diabetics. Australas Med J. 2014 Jan 31;7(1):29-34. doi: 10.4066/AMJ.2014.1906. eCollection 2014.</citation>
    <PMID>24567764</PMID>
  </reference>
  <reference>
    <citation>Masajtis-Zagajewska A, Nowicki M. New markers of urinary tract infection. Clin Chim Acta. 2017 Aug;471:286-291. doi: 10.1016/j.cca.2017.06.003. Epub 2017 Jun 13. Review.</citation>
    <PMID>28622967</PMID>
  </reference>
  <reference>
    <citation>Liu J, Li L, Li S, Jia P, Deng K, Chen W, Sun X. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. Sci Rep. 2017 Jun 6;7(1):2824. doi: 10.1038/s41598-017-02733-w. Review.</citation>
    <PMID>28588220</PMID>
  </reference>
  <reference>
    <citation>Li D, Wang T, Shen S, Fang Z, Dong Y, Tang H. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017 Mar;19(3):348-355. doi: 10.1111/dom.12825. Epub 2016 Dec 19.</citation>
    <PMID>27862830</PMID>
  </reference>
  <reference>
    <citation>Yu H, Woo VC. Emerging use of combination therapies for the management of type 2 diabetes - focus on saxagliptin and dapagliflozin. Diabetes Metab Syndr Obes. 2017 Jul 21;10:317-332. doi: 10.2147/DMSO.S117982. eCollection 2017. Review.</citation>
    <PMID>28769579</PMID>
  </reference>
  <reference>
    <citation>Del Prato S, Rosenstock J, Garcia-Sanchez R, Iqbal N, Hansen L, Johnsson E, Chen H, Mathieu C. Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin. Diabetes Obes Metab. 2018 Jun;20(6):1542-1546. doi: 10.1111/dom.13258. Epub 2018 Mar 25.</citation>
    <PMID>29446523</PMID>
  </reference>
  <reference>
    <citation>Kim NH, Yu T, Lee DH. The nonglycemic actions of dipeptidyl peptidase-4 inhibitors. Biomed Res Int. 2014;2014:368703. doi: 10.1155/2014/368703. Epub 2014 Jul 21. Review.</citation>
    <PMID>25140306</PMID>
  </reference>
  <reference>
    <citation>Lewis DA, Brown R, Williams J, White P, Jacobson SK, Marchesi JR, Drake MJ. The human urinary microbiome; bacterial DNA in voided urine of asymptomatic adults. Front Cell Infect Microbiol. 2013 Aug 15;3:41. doi: 10.3389/fcimb.2013.00041. eCollection 2013.</citation>
    <PMID>23967406</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 22, 2021</study_first_submitted>
  <study_first_submitted_qc>January 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 2, 2021</study_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pisa</investigator_affiliation>
    <investigator_full_name>Anna Solini</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>UTI</keyword>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>SGLT2 inhibitors</keyword>
  <keyword>DPP4 inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Linagliptin</mesh_term>
    <mesh_term>Saxagliptin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

